Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CTSD | P07339 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27766567 | 0.87 | CTSD (0.65) | STAT3RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL6324990 | 0.86 | KLKB1 (0.57) | STAT3RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL11245542 | 0.81 | CA1 (0.62) | STAT3RAB9AGAALMNACA1 | |
| SCHEMBL12857990 | 0.81 | STAT3 (0.73) | STAT3RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL23084665 | 0.81 | STAT3 (0.72) | STAT3RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL6453448 | 0.80 | NPC1 (1.00) | STAT3RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL12387872 | 0.80 | RAB9A (0.73) | STAT3RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL11272638 | 0.79 | CTSD (0.69) | STAT3RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL295407 | 0.79 | CTSD (1.00) | STAT3RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL13527481 | 0.79 | CTSD (0.73) | STAT3RAB9ANPC1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110070297-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20070197532-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197532-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007061923-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197532-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | STAT3 1741/4885RAB9A 3614/4885NPC1 2902/4885 |
| US-20110070297-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | STAT3 1741/4885RAB9A 3614/4885NPC1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.